LXRβ regulates the expression of immune response gene sets and lipids known to be involved in immune modulation (56) and these works imply that targeting the mevalonate pathway could disturb ferroptosis and immunity in glioma. This evidence concerns the gene NR1H2 and central nervous system cancer.